CoChat

Suicidal Behavior and Depression in Smoking Cessation Treatments

Open access
Moore, Thomas J., Furberg, Curt D., Glenmullen, Joseph, Maltsberger, John T., Singh, Sonal · 2011 · PLoS ONE

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Two treatments for smoking cessation--varenicline and bupropion--carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increased risk in smoking or smoking cessation independent of treatment, and differences between drugs are unknown. METHODOLOGY: From the FDA's Adverse Event Reporting System (AERS) database from 1998 through September 2010 we selected domestic, serious case reports for varenicline (n = 9,575), bupropion for smoking cessation (n = 1,751), and nicotine replacement products (n = 1,917). A composite endpoint of suicidal/self-injurious behavior or depression was defined as a case with one or more Preferred Terms in Standardized MedDRA Query (SMQ) for those adverse effects. The main outcome measure was the ratio of reported suicide/self-injury or depression cases for each drug compared to all other serious events for that drug. RESULTS: Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement. Compared to nicotine replacement, the disproportionality results (OR (95% CI)) were varenicline 8.4 (6.8-10.4), and bupropion 2.9 (2.3-3.7). The disproportionality persisted after excluding reports indicating concomitant therapy with any of 58 drugs with suicidal behavior warnings or precautions in the prescribing information. An additional antibiotic comparison group showed that adverse event reports of suicidal/self-injurious behavior or depression were otherwise rare in a healthy population receiving short-term drug treatment. CONCLUSIONS: Varenicline shows a substantial, statistically significant increased risk of reported depression and suicidal/self-injurious behavior. Bupropion for smoking cessation had smaller increased risks. The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0027016

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Varenicline, bupriopion versus nicotine replacement.
Figure 1 Varenicline, bupriopion versus nicotine replacement.CC BY · PubMed Central
Figure 2 Varenicline, bupropion versus 3 antibiotics.
Figure 2 Varenicline, bupropion versus 3 antibiotics.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 4

  1. M Levenson, 2008, Statistical Review and Evaluation: Anti-epileptic Drugs and Suicidality
  2. 2010, The Adverse Event Reporting System (AERS): Latest Quarterly Data File
  3. H Josefberg, 2006, Clinical Safety Review Application 21-928 Varenicline tartrate
  4. C Winchell, 2006, Supervisory Review of NDA: Safety Review and Primary Clinical Efficacy Review Varenicline Pfizer Inc.U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Cited by

See all 155

Metadata

Authors
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S.
Affiliations
  • Institute for Safe Medication Practices (US)
  • Wake Forest University Health Sciences (US)
  • Harvard University (US)
  • Johns Hopkins University (US)
Corresponding author
Moore, Thomas J.
Venue
PLoS ONE
Published
2011-11-02
Volume
6
Issue
11
Pages
e27016
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2081459939
Cited by
150
References
29
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 11 · 2017: 10 · 2016: 17 · 2015: 11 · 2014: 9 · 2013: 30 · 2012: 27
FWCI
15.49
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
Keywords
smoking cessation, varenicline, bupropion, nicotine replacement therapy, suicidal behavior, self-harm, depression, adverse drug reactions, drug safety, FDA boxed warning, disproportionality analysis, serious adverse events
MeSH terms
Varenicline, Adult, Benzazepines, Depression, Female, Humans, Male, Middle Aged, Nicotine, Quinoxalines, Suicide, Smoking Cessation, Bupropion, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suicidal Behavior and Depression in Smoking Cessation Treatments. https://app.cochat.ai/papers/10.1371/journal.pone.0027016
The paper
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011). Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE. https://doi.org/10.1371/journal.pone.0027016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.